Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

Overview of attention for article published in Frontiers in Pharmacology, August 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 8,049 followers.

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer https://t.co/WvxH30ttVX

New Research: Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer https://t.co/FrflOn8XIX #pharmacology

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.